THE OTHER SIDE OF GLP-1 Beyond Weight Loss and the Number on the Scale

SoulSpring Wellness Journal™ · Volume 01 · Issue 04

There is no denying it.

GLP-1 medications have changed the conversation around weight loss.

The results can be dramatic. The number on the scale goes down. Clothing sizes change. People are celebrating finally feeling like they have found something that works.

But somewhere along the way, I think we started paying so much attention to the weight being lost that we stopped asking an equally important question.

What else is being lost?

Because the human body is not a number on a scale.

And weight loss, regardless of how quickly or successfully it happens, does not automatically tell us the whole story about what is happening beneath the surface.

GLP-1 medications, including medications containing semaglutide and tirzepatide, have provided meaningful benefits for some people. They can also come with risks, side effects, and unanswered questions that deserve a more honest conversation.

This is about informed decisions.

Because people deserve to understand the full picture before making decisions about their bodies.

WE KNOW ABOUT THE COMMON SIDE EFFECTS.

Nausea.

Constipation.

Vomiting.

Diarrhea.

Stomach pain.

Digestive changes.

These are the side effects most people have probably heard about.

GLP-1 medications slow gastric emptying and reduce appetite. For some people, that can mean feeling full much faster, eating significantly less, and experiencing changes throughout the digestive system. 

But the conversation cannot end there.

Because there are other things happening that deserve our attention too.

THE NUMBER ON THE SCALE WILL NEVER TELL THE WHOLE STORY.

When someone loses a significant amount of weight, we should be asking more than:

How much weight did you lose?

We should also be asking:

What was the weight made of?

Weight loss can include fat, but research shows it can also involve losses in lean body mass. Recent systematic reviews examining GLP-1 medications used for obesity management found reductions in absolute lean mass alongside overall weight loss. Researchers emphasize the importance of nutritional and exercise strategies that support muscle preservation during treatment. 

Muscle matters.

Especially as we get older.

Muscle supports strength, mobility, balance, metabolism, bone health, and ultimately, independence.

So when someone loses a significant amount of weight, the question cannot simply be whether the number is going down.

We also need to be asking what is happening to the body as a whole.

AND THEN THERE IS HAIR LOSS.

More people are talking about it.

Thinning.

Shedding.

Hair coming out in the shower.

Hair that suddenly feels different.

Recent systematic reviews have found an association between certain GLP-1 medications and reported hair loss. Semaglutide and tirzepatide have been identified more frequently in the available evidence, although researchers are still working to understand the exact relationship. Rapid weight loss itself may also contribute, and telogen effluvium, a form of diffuse shedding that can occur following physiological stress, is one possible explanation. 

That does not mean every person taking a GLP-1 medication will experience hair loss.

But if it is happening, people deserve to know that they are not imagining it.

And they deserve to understand that rapid changes in the body can have consequences beyond the number on the scale.

AND THEN THERE ARE THE MORE SERIOUS RISKS.

This is the part of the conversation that I believe needs to be much louder.

Not everyone taking these medications will experience serious complications.

Many will not.

But serious adverse effects are included in current prescribing information, and they deserve to be part of an honest conversation.

PANCREATITIS

Pancreatitis is inflammation of the pancreas, and it can be serious.

Current prescribing information for medications including Wegovy and Zepbound warns about acute pancreatitis. The information specifically notes that severe forms of pancreatitis, including hemorrhagic or necrotizing pancreatitis, have been observed in patients treated with GLP-1 medications. 

Symptoms may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea and vomiting. 

That is not a minor side effect.

And it should not be treated like one.

GALLBLADDER PROBLEMS

GLP-1 medications are also associated with an increased occurrence of gallbladder problems, including gallstones and inflammation of the gallbladder.

Current prescribing information for Wegovy and Zepbound includes warnings regarding acute gallbladder disease. Rapid or substantial weight loss can itself increase the risk of gallbladder problems. 

Pain in the upper abdomen, fever, yellowing of the skin or eyes, or other concerning symptoms should always be evaluated by a medical professional.

SEVERE DIGESTIVE COMPLICATIONS

Slowing gastric emptying is part of how these medications work.

For some people, however, gastrointestinal effects can become severe.

Current prescribing information warns that GLP-1 medications can be associated with severe gastrointestinal adverse reactions. Wegovy and Zepbound are also not recommended for people with severe gastroparesis. 

When your digestion changes significantly, the effects can extend beyond simply feeling nauseated.

Digestion influences hydration.

Nutrition.

Energy.

And how the body functions as a whole.

That is why severe or persistent digestive symptoms should never be ignored.

DEHYDRATION AND KIDNEY PROBLEMS

Nausea.

Vomiting.

Diarrhea.

Reduced food intake.

Reduced fluid intake.

When those things happen together, dehydration can become a serious concern.

Current prescribing information warns of acute kidney injury related to volume depletion. Some reported cases have occurred in people experiencing significant gastrointestinal side effects that led to dehydration. 

Again, this does not mean it happens to everyone.

But it does mean that people should understand the potential risk.

CHANGES IN VISION

For some people with type 2 diabetes, vision changes are another important consideration.

Current prescribing information for semaglutide and tirzepatide includes precautions regarding diabetic retinopathy complications in people with type 2 diabetes. Patients with a history of diabetic retinopathy may require monitoring for changes or progression. 

Medication decisions should never be made based on a before-and-after photo alone.

The body is more complicated than that.

SERIOUS ALLERGIC REACTIONS

Although uncommon, serious hypersensitivity reactions have been reported with these medications.

These can include anaphylaxis and angioedema. 

Symptoms of a serious allergic reaction can include swelling, difficulty breathing or swallowing, hives, or other severe symptoms.

These require immediate medical attention.

LOW BLOOD SUGAR

For people taking GLP-1 medications alongside insulin or certain medications that increase insulin secretion, low blood sugar can also become a concern.

Current prescribing information warns that the risk of hypoglycemia may increase when these medications are used together. 

The risks are not identical for every person.

They can depend on the medication being taken, the dose, other medications, underlying health conditions, and individual circumstances.

Which is why one-size-fits-all conversations about these drugs simply do not work.

THYROID TUMOR WARNINGS

Certain GLP-1 medications also carry warnings regarding thyroid C-cell tumors.

These medications caused thyroid C-cell tumors in rodents. Whether this translates to the same risk in humans is not known. Current prescribing information includes contraindications for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. 

That does not mean that every person taking these medications will develop thyroid cancer.

It means that the warning exists.

And people deserve to understand it.

AND WHAT ABOUT DESIRE, MOTIVATION, AND PLEASURE?

There is another conversation beginning to emerge.

Some people are describing changes in desire.

Motivation.

Pleasure.

Their relationship with food.

Their relationship with alcohol.

Their relationship with other rewarding behaviors.

And yes, some people are also asking questions about changes in libido.

The research in this area is still emerging and the human evidence remains limited and mixed. A recent review examining GLP-1 receptor agonists and sexual function found that the available evidence is still heterogeneous and that more controlled research is needed. 

This is an area where we need to be especially careful.

We should not make claims that science has not yet established.

But we also should not dismiss people’s experiences simply because the research has not caught up enough to explain them.

Sometimes people begin asking questions before science has all the answers.

And I think we should listen.

APPETITE FOR LIFE.

Maybe one of the biggest questions we should be asking is this:

What happens when we become so focused on suppressing appetite that we stop talking about appetite as something larger than food?

We have an appetite for nourishment.

For movement.

For connection.

For pleasure.

For creativity.

For intimacy.

For life.

That does not mean a GLP-1 medication takes those things away.

It means that when people begin describing changes in how they experience desire, motivation, pleasure, or reward, those experiences deserve curiosity instead of dismissal.

The human body is complicated.

The human experience is even more complicated.

And sometimes what we lose cannot be measured on a scale.

SO WHAT DO WE DO WITH ALL OF THIS?

We ask better questions.

Before starting a medication that can dramatically change the way our body functions, perhaps we should ask:

What are the potential benefits for me?

What are the known risks?

What side effects should I be watching for?

How will I protect my muscle mass?

How will I make sure I am getting adequate nutrition?

What happens if I experience severe digestive symptoms?

What happens if I develop pancreatitis, gallbladder problems, or other complications?

How long do I expect to take this medication?

What happens if I stop?

And perhaps most importantly:

Am I making this decision with the full picture in front of me?

THE SOULSPRING PERSPECTIVE

At SoulSpring, I believe informed decisions begin with honest conversations.

I am not here to tell anyone what they should do with their body.

That decision is deeply personal.

And for some people, GLP-1 medications may offer meaningful benefits.

But I also believe that benefits and risks deserve equal attention.

We cannot talk about dramatic weight loss without also talking about muscle.

We cannot talk about suppressed appetite without also talking about nutrition.

We cannot talk about nausea and constipation without acknowledging the possibility of more serious digestive complications.

We cannot talk about before-and-after photos without asking what might be happening behind them.

And we cannot ignore pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration, kidney complications, vision changes, serious allergic reactions, and other potentially serious risks simply because the conversation is more complicated than a success story.

The body deserves more than a number on a scale.

Health deserves more than a number on a scale.

And people deserve to make decisions with their eyes wide open.

That is not fear.

That is being informed.

SOURCES

Gupta, Aditya K., Elizabeth M. Teasell, Vasiliki Economopoulos, and Paradi Mirmirani. “GLP-1 Therapies and Hair Loss: A Systematic Review of Current Evidence and Implications for Counseling.” Science Progress, vol. 109, no. 2, 2026. DOI: 10.1177/00368504261444578. This systematic review examined the available evidence regarding GLP-1 receptor agonists and hair loss, including reported associations involving semaglutide and tirzepatide and the potential role of rapid weight loss and telogen effluvium. 

Cheng, Po-Lung, and Hua-Ching Chang. “Glucagon-Like Peptide-1 Receptor Agonists and Hair Loss: A Systematic Review and Meta-Analysis.” Diabetes Research and Clinical Practice, vol. 237, 2026, article 113333. DOI: 10.1016/j.diabres.2026.113333. This meta-analysis evaluated available interventional studies examining the association between GLP-1 receptor agonist use and hair loss. 

Laverde, Ligia Patricia, Oscar Mauricio Muñoz-Velandia, Diana Alfonso, et al. “Effect of GLP-1 Receptor Agonists at Doses for Obesity Management on Muscle Health: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” International Journal of Obesity, 2026. This systematic review and meta-analysis examined the effects of GLP-1 receptor agonists on lean mass and body composition in people receiving these medications for obesity management. 

Jobanputra, Rishi, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, and Thomas Yates. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/Metabolism Research and Reviews, vol. 42, no. 5, 2026. DOI: 10.1002/dmrr.70194. This review examined changes in lean body mass associated with these medications in human clinical trials. 

U.S. National Library of Medicine. “Tirzepatide Injection.” MedlinePlus Drug Information. This consumer medication resource provides information regarding the uses, warnings, precautions, and potential side effects associated with tirzepatide. 

U.S. Food and Drug Administration and National Library of Medicine. “WEGOVY® (semaglutide) Prescribing Information.” Current prescribing information includes warnings and precautions involving acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, serious hypersensitivity reactions, diabetic retinopathy complications, and thyroid C-cell tumor risk. 

U.S. Food and Drug Administration and National Library of Medicine. “ZEPBOUND® (tirzepatide) Prescribing Information.” Current prescribing information includes warnings and precautions involving severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia, diabetic retinopathy considerations, and thyroid C-cell tumor risk. 

Merhi, Zaher. “GLP-1 Receptor Agonists and Sexual Function in Women and Men: A Narrative Review of Emerging Evidence and the Need for Further Research.” Sexual Medicine Reviews, vol. 14, no. 1, 2026. DOI: 10.1093/sxmrev/qeag015. This review examined emerging evidence regarding GLP-1 receptor agonists, libido, sexual function, reward-related behaviors, and the need for additional controlled human research. 

Important note about the research: The science surrounding GLP-1 medications continues to evolve. Some risks and side effects are established in current medication labeling and clinical research. Other reported experiences remain under active investigation. Not every person taking a GLP-1 medication will experience these side effects or complications.

But serious risks deserve to be part of the conversation.

So do the questions we have not fully answered yet.

That is exactly why we ask them.

A NOTE FROM SOULSPRING

Thank you for joining us for Volume 01 · Issue 04 of the SoulSpring Wellness Journal™.

Our intention with this series is to create a thoughtful space for conversations that deserve more than a headline, a social media post, or a before-and-after photo.

Health is complicated.

Bodies are complicated.

And asking questions is not the same thing as creating fear.

We believe in curiosity.

We believe in education.

We believe in listening to our bodies and taking our experiences seriously.

Most of all, we believe that every person deserves access to information that allows them to make decisions from a place of awareness and understanding.

The conversation around GLP-1 medications is still unfolding.

And we will continue asking questions.

Until next time,

SoulSpring Oasis

IMPORTANT NOTE: This article is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice. The information in this article is not a substitute for individualized medical care. Always consult a qualified healthcare professional regarding medications, symptoms, side effects, and decisions related to your personal health. Never stop or change a prescribed medication without speaking with your healthcare provider first.